Franklin Street Advisors’s Theriva Biologics TOVX Stock Holding History

Franklin Street Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-15	Closed	-$31K	–	166
2018 Q2	$31K	Buy	15 +1	+7%	+$2.3K	﹤0.01%	159
2018 Q1	$40K	Hold	14	–	–	0.01%	163
2017 Q4	$64K	Buy	14 +8	+133%	+$50K	0.01%	163
2017 Q3	$49K	Hold	6	–	–	0.01%	156
2017 Q2	$29K	Sell	6 -8	-57%	-$39.8K	0.01%	149
2017 Q1	$79K	Hold	14	–	–	0.01%	153
2016 Q4	$96K	Hold	14	–	–	0.02%	165
2016 Q3	$217K	Hold	14	–	–	0.04%	166
2016 Q2	$227K	Hold	14	–	–	0.04%	175
2016 Q1	$297K	Buy	14 +6	+75%	+$90.2K	0.06%	178
2015 Q4	$169K	Hold	8	–	–	0.03%	210
2015 Q3	$168K	Hold	8	–	–	0.03%	209
2015 Q2	$211K	Buy	+8	New	+$161K	0.04%	205

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Franklin Street Advisors's TOVX Position: Q3 2018 in Review

Franklin Street Advisors sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 15 shares — an estimated $31K sold.

Franklin Street Advisors first reported a position in TOVX in Q2 2015 and held it in 13 quarters. The position peaked at $297K in Q1 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Franklin Street Advisors reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Franklin Street Advisors sold 15 Theriva Biologics shares in Q3 2018, an estimated $31K.
Franklin Street Advisors first reported a position in Theriva Biologics in Q2 2015 and held it in 13 quarters.
Franklin Street Advisors's Theriva Biologics position peaked at $297K in Q1 2016.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Franklin Street Advisors's 13F filing for Q3 2018, filed 5 Oct 2018.